Top Markets
#1 ONFA ONFA +225.76%
#2 Resolv wstUSR Resolv wstUSR +198.02%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +38.13%
#6 NKN NKN +36.26%
#7 StakeStone StakeStone +28.59%
#8 BLOCKv BLOCKv +26.08%
#9 KONET KONET +24.91%
#10 OpenVPP OpenVPP +22.33%
Coin of the day
ONFA ONFA
設定
言語
日本
通貨
USD
テーマ
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
株式のランク #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
株価
$0.5275
時価総額
$1.25M
変化（1日）
-3.56%
変化（1年）
-83.77%
国
US
取引 Ensysce Biosciences, Inc. (ENSC)

カテゴリー

Healthcare
Ensysce Biosciences, Inc.（ENSC）の収益
Sep 2025 時点の収益 TTM: $4.49M
Ensysce Biosciences, Inc. の最新の財務報告によると、現在の収益 (TTM) は $4.49M です。2023 年には $2.23M の収益があり、これは 2022 年の $2.52M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Ensysce Biosciences, Inc. の収益履歴（2017 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) $4.49M -13.85%
2024 $5.21M 133.53%
2023 $2.23M -11.59%
2022 $2.52M -28.54%
2021 $3.53M -10.18%
2020 $3.93M 122.86%
2019 $1.76M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
同業他社の収益
企業 収益 収益の差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 1,079,095.70%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 268,123.28%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 319,469.02%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 202,258.79%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 349,599.93%
AU